Showing 1271-1280 of 5771 results for "".
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- Iantrek Announces US Commercial Launch of AlloFlo Uveo, First Surgical Treatment Targeting the Uveoscleral Pathwayhttps://modernod.com/news/iantrek-announces-us-commercial-launch-of-alloflo-uveo-first-surgical-treatment-targeting-the-uveoscleral-pathway/2484180/Iantrek announced the official US commercial launch of AlloFlo Uveo, the first surgical treatment specifically designed to target the uveoscleral pathway. This milestone follows Iantrek’s $42 million Se
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- Glaukos to Highlight Innovations at the 2025 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-to-highlight-innovations-at-the-2025-american-academy-of-ophthalmology-annual-meeting/2484175/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-20, 2025, in Orlando. Glaukos will be exhibiting onsite at booth #2921.
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement
- Horizon Surgical Systems Announces World’s First Robotic Cataract Surgery Using the Polaris Platformhttps://modernod.com/news/horizon-surgical-systems-announces-worlds-first-robotic-cataract-surgery-using-the-polaris-platform/2484160/Horizon Surgical Systems announced the completion of the world’s first cataract surgery performed using its Polaris robotic platform. The milestone procedure was conducted by Uday Devgan, MD, FACS.
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- Ziemer USA Announces New Innovations for the Galilei Diagnostic Platform and FEMTO LDV Z8 Femtosecond Laserhttps://modernod.com/news/ziemer-usa-announces-new-innovations-for-the-galilei-diagnostic-platform-and-femto-ldv-z8-femtosecond-laser-platform/2482904/Ziemer USA, in partnership with CorneaGen, announced the launch of the Galilei CTAK module, which is now available for use with the Galilei diagnostic platform. "We are thrilled to complete our product offering for CTAK patients. With the addition of the Galilei CTAK module in combination
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin